Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Price History  |  Ratios  |  Insiders

Breaking & Recent News Traws Pharma Inc TRAW

Healthcare Biotechnology
Traws Pharma, Inc., a clinical-stage biopharmaceutical company, develops small-molecule oral product candidates for respiratory viral diseases and cancer. The company is developing investigational novel therapies for influenza and COVID-19 that are designed to address treatment resistance, such as TRX01 (Ratutrelvir), an inhibitor in development for the treatment of COVID-19; and Tivoxavir... see more

Recent & Breaking News (NDAQ:TRAW)

Traws Pharma Completes Analysis of Ratutrelvir Clinical Study in PAXLOVID®-Eligible and Ineligible COVID-19 Patients and Provides Updates for Additional Indication for Tivoxavir Marboxil as a Prophylactic Treatment for Seasonal Influenza

GlobeNewswire February 19, 2026

Traws Pharma Completes Enrollment of Ratutrelvir Clinical Study in PAXLOVID®-Eligible and Ineligible COVID-19 Patients; Announces Plans for Added Indication for Tivoxavir Marboxil as a Prophylactic Treatment for Seasonal Influenza

GlobeNewswire January 26, 2026

Traws Pharma Files Tivoxavir Marboxil Investigational New Drug (IND) Application for Influenza Therapy, and Provides Updated Results from the Ongoing Clinical Study of Ratutrelvir in PAXLOVID®-Eligible and Ineligible COVID-19 Patients

GlobeNewswire January 13, 2026

Traws Pharma Reports Positive Interim Clinical Data with Ratutrelvir Versus PAXLOVID(TM), Shows Activity in PAXLOVID-Ineligible COVID-19 Patients

GlobeNewswire December 17, 2025

Traws Pharma Reports Third Quarter 2025 Results and Business Highlights

GlobeNewswire November 13, 2025

ChemDiv Extends CMC Services Collaboration for Ratutrelvir, a Potential Best-in-Class COVID-19 Therapeutic Advancing in Phase 2 Clinical Trials

PR Newswire October 30, 2025

Dover, Delaware -- Expert Systems Inc., a leading life sciences accelerator, Supports Traws Pharma Phase 2 Clinical Studies of Ratutrelvir -- a Novel Ritonavir-Free Antiviral for COVID-19.

PR Newswire October 22, 2025

Traws Pharma Doses First Patient with Ratutrelvir in Phase 2 COVID Studies, Expects Results by Year-End 2025

GlobeNewswire October 14, 2025

Traws Pharma Adds John Leaman, MD, as Independent Director and Formalizes Appointments of Two Key Executives

GlobeNewswire October 6, 2025

Annovis Appoints Mark Guerin as Chief Financial Officer

GlobeNewswire September 25, 2025

Traws Pharma Receives Approval to Proceed with Phase 2 COVID Studies with Ratutrelvir, Expects Results by Year-End 2025

GlobeNewswire August 18, 2025

Traws Pharma Reports Second Quarter 2025 Results and Business Highlights

GlobeNewswire August 14, 2025

Traws Pharma to Report Second Quarter 2025 Financial Results on Thursday, August 14, 2025

GlobeNewswire August 8, 2025

Traws Pharma Advances Antiviral Pipeline with Multiple Regulatory Submissions

GlobeNewswire June 30, 2025

Traws Pharma Announces Publication of Compelling Efficacy data in RDEB SCC Patients Treated with Legacy Oncology Drug Rigosertib

GlobeNewswire June 3, 2025

Traws Pharma Reports First Quarter 2025 Results and Business Highlights

GlobeNewswire May 15, 2025

Traws Pharma Reports Full Year 2024 Results and Business Highlights

GlobeNewswire March 31, 2025

Traws Pharma Announces Management Updates

GlobeNewswire March 28, 2025

Traws Pharma to Host Investor Event on Bird Flu and COVID Product Candidates Virtual Event to be Held on Monday, March 31, 2025 at 10:00 AM ET

GlobeNewswire March 26, 2025

Traws Pharma's COVID-19 Candidate, Ratutrelvir, Presented at ICAR

GlobeNewswire March 25, 2025

Podcasts